Soft Tissue Sarcoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Soft Tissue Sarcoma Epidemiology Forecast Report Coverage

Expert Market Research's “Soft Tissue Sarcoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of soft tissue sarcoma. It projects the future incidence and prevalence rates of soft tissue sarcoma cases across various populations. The study covers age, gender, and type as major determinants of the soft tissue sarcoma population. The report highlights patterns in the prevalence of soft tissue sarcoma over time and projects future trends based on multiple variables.

Soft Tissue Sarcoma Understanding: Disease Overview

Soft tissue sarcoma (STS) is a diverse group of malignant tumors arising from mesenchymal tissues such as fat, muscle, nerves, and blood vessels. Over 50 histological subtypes exist, with leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma among the most prevalent. These tumors can occur in any part of the body, but the extremities are most frequently affected. Although STS can develop at any age, incidence increases with advancing age and is slightly more common in males. Delayed diagnosis is frequent due to nonspecific symptoms and the tumor’s deep-seated growth.

Soft Tissue Sarcoma Epidemiology Perspective

The soft tissue sarcoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for soft tissue sarcoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for soft tissue sarcoma and their trends. The soft tissue sarcoma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In the United States, soft tissue sarcoma (STS) is expected to affect around 13,590 individuals and result in 5,200 deaths in 2025, with a higher incidence observed among males than females.
• In Japan, the age-standardized incidence rate stood at approximately 4.48 per 100,000 in 2021, with localized stages accounting for ~60% of incident cases.
• In Spain, 85.7% of patients underwent surgery and 37.1% received radiotherapy, highlighting the country’s reliance on a multimodal therapeutic approach.
• In India, soft tissue sarcoma represents 0.68% of all malignancies, with majority cases occurring in male patients and involving the lower extremities, particularly the thighs.

Read more about this report - Request a Free Sample

Country-wise Soft Tissue Sarcoma Epidemiology Segment

The soft tissue sarcoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiological outlook for soft tissue sarcoma (STS) reveals varying trends across age groups, geographies, and subtypes. In the United States, soft tissue sarcoma (STS) remains a rare cancer, accounting for less than 1% of all adult malignancies, with incidence increasing with age and more common in men, as noted by the American Cancer Society. A retrospective study in India found a predominance of STS among males, especially in the lower limbs, and in the 41-50 age group. Meanwhile, in the United Kingdom, the five-year survival rate ranges from 55% to 60%, largely dependent on the histologic subtype, tumor size, and stage at diagnosis, with earlier detection associated with better prognosis. These regional patterns underscore the heterogeneity of soft tissue sarcoma presentation and outcomes, emphasizing the need for context-specific strategies in diagnosis, treatment, and long-term management.

Soft Tissue Sarcoma: Treatment Overview

The treatment of soft tissue sarcoma (STS) relies on a multidisciplinary approach involving surgery, radiation therapy, and systemic therapies. Limb-sparing surgeries are now standard in specialized centers, often combined with radiotherapy to improve local control. Chemotherapy, typically involving doxorubicin-based regimens, is considered for high-grade or metastatic cases, while targeted therapies such as pazopanib and investigational agents are used in specific subtypes. Advances in molecular diagnostics have also allowed precision medicine approaches, particularly in recurrent or treatment-resistant tumors, improving treatment personalization and offering better outcomes for patients with rare histologic variants.

Key Questions Answered

• What are the key findings of soft tissue sarcoma epidemiology in the 8 major markets?
• What will be the total number of patients with soft tissue sarcoma across the 8 major markets during the forecast period?
• What was the country-wise soft tissue sarcoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of soft tissue sarcoma patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of soft tissue sarcoma during the forecast period of 2026-2035?
• What are the currently available treatments for soft tissue sarcoma?
• What are the disease risks, signs, symptoms, and unmet needs of soft tissue sarcoma?

Scope of the Soft Tissue Sarcoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of soft tissue sarcoma based on several factors.
• Soft Tissue Sarcoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The soft tissue sarcoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Synovial Sarcoma Market Report and Forecast

Soft Tissue Sarcoma Market Report and Forecast